Skip to main content
Science / Explained
SERIES: Reading What Actually MattersArticle 1 of 5

How to Read a COA Without a Science Background

A Certificate of Analysis is not a document written for experts. It is a structured record meant to connect a compound, a batch, a test method, and a result into one traceable story.

A Certificate of Analysis can look more intimidating than it is.

At first glance, it appears to be a document written for someone else. It has tables, numbers, technical terms, abbreviations, testing methods, dates, signatures, and result lines that may not explain themselves clearly. The document looks official, but official does not always mean understandable.

That is where many people get stuck. They either trust the COA because it exists, or they ignore it because it feels too technical to read. Both reactions miss the point. A COA is not supposed to be decoration. It is supposed to help connect a specific material to specific testing results.

THE DOCUMENT

A COA should answer a few basic questions before it answers anything more advanced.

What was tested? Which batch or lot was tested? Who performed the testing? What methods were used? What results were found? Do those results match the specifications being claimed?

Those questions matter because a COA is only useful when it is specific. A generic document may look impressive, but if it is not clearly tied to the material being evaluated, it does not provide the level of clarity people often assume it does.

In pharmaceutical and active ingredient quality systems, documentation is not treated as a casual attachment. Batch production and laboratory control records are reviewed before release, and quality records are part of how materials are evaluated against specifications. That is the broader logic a reader should bring to any COA: the document should connect the material, the batch, the test, and the result into one traceable story. (database.ich.org)

WHAT TO LOOK FOR FIRST

The first thing to look for is identity.

Identity answers the most basic question: is this the compound it is supposed to be? If identity is unclear, the rest of the document becomes less meaningful. Purity does not help much if the document does not clearly establish what compound was tested.

The second thing to look for is the batch or lot connection. The document should not feel detached from the product. A COA becomes more useful when the batch number, lot number, or identifying reference connects the test results to the specific batch being offered.

The third thing to look for is the method. The method tells you how the result was generated. In synthetic peptide quality discussions, identity, purity, impurities, assay, and related quality attributes are central areas of evaluation. Those areas are not just technical details. They are the structure that allows the document to be interpreted. (U.S. Food and Drug Administration)

WHAT THE COA DOES NOT DO

A COA does not remove every question.

It does not tell the full story of how the compound was produced. It does not prove how every step was handled before or after testing. It does not replace broader sourcing discipline, fulfillment controls, storage expectations, or supplier qualification.

That does not make the COA unimportant.

It means the COA should be read correctly. It is not the entire trust system. It is one important part of that system.

The mistake is treating the document as either everything or nothing. A COA is neither. It is a structured piece of evidence that becomes more useful when the reader knows how to connect its parts.

What this means

Reading a COA does not require a science background.

It requires a better order of attention.

Start with identity. Then look for the batch connection. Then look at purity. Then look at the testing method. Then ask whether the results are specific enough to explain what is being presented.

A COA should reduce uncertainty.

If it only creates the appearance of certainty, but does not clearly connect compound, batch, method, and result, then it has not done enough.

Catalyst's own Certificate of Analysis page is built exactly this way: report number, batch, and method are each explained in plain language, and every vial's QR opens its specific batch report.

A COA should reduce uncertainty, not just create the appearance of certainty.

Next →
What Purity Percentages Actually Mean
References6 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Public UpdateNews or announcements
MechanismCell and pathway logic
Show 3 more source types
Official LabelRegulator documents
Human TrialStudies in people
ReviewExpert synthesis
  1. Public Update

    USP reference-standards documentation for synthetic peptide therapeutics

    U.S. Pharmacopeia

    Reference Standards to Support Quality of Synthetic Peptide Therapeutics Read source

    Used Here For

    Explaining the reference-standard system a COA's purity numbers should ultimately trace back to, in plain terms for non-scientist readers.

    Good For

    Understanding the official quality-standards infrastructure behind reputable peptide manufacturing.

    Not For

    Verifying any single product's actual compliance with these standards.

    Pharmaceutical Research 40(6):1317-1328
  2. Public Update

    FDA guidance for industry: ANDAs for highly purified synthetic peptide drug products

    U.S. Food and Drug Administration

    ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry Read source

    Used Here For

    Grounding what 'highly purified' is supposed to mean at a regulatory level, background for reading a COA.

    Good For

    The regulatory bar FDA set in 2021 for the purity and characterization of synthetic peptide drugs.

    Not For

    Assuming a product meets this bar because it cites it, or treating it as current FDA policy: FDA withdrew this guidance in July 2026.

    U.S. Food and Drug Administration, May 2021 (Federal Register notice of availability); withdrawn by FDA in July 2026
  3. Public Update

    ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

    International Council for Harmonisation

    Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Read source

    Used Here For

    Explaining the global manufacturing-quality framework that legitimate COAs are built on top of.

    Good For

    The internationally recognized manufacturing-quality framework a credible COA should trace back to.

    Not For

    Confirming any specific manufacturer actually follows this framework.

    ICH Harmonised Tripartite Guideline, Step 4, November 10, 2000
  4. Public Update

    FDA guidance: Q2(R2) Validation of Analytical Procedures

    U.S. Food and Drug Administration

    Q2(R2) Validation of Analytical Procedures Read source

    Used Here For

    Explaining why the test method itself needs validation, not just the number a COA reports.

    Good For

    Understanding what it means for a lab's test method itself to be validated, not just its result.

    Not For

    Verifying whether a specific lab's method was actually validated.

    U.S. Food and Drug Administration, guidance for industry (ICH Q2(R2)), March 2024
  5. Public Update

    FDA guidance for industry: Data Integrity and Compliance With Drug CGMP

    U.S. Food and Drug Administration

    Data Integrity and Compliance With Drug CGMP: Questions and Answers Guidance for Industry Read source

    Used Here For

    Explaining the recordkeeping standards a trustworthy COA is expected to meet.

    Good For

    Understanding the recordkeeping and data-integrity expectations behind a trustworthy COA.

    Not For

    Confirming any specific document's authenticity; that requires direct verification.

    U.S. Food and Drug Administration, December 2018
  6. Mechanism

    PolyPeptide technical paper: Control Strategies for Synthetic Therapeutic Peptide APIs, Part I

    PolyPeptide Group

    Control Strategies for Synthetic Therapeutic Peptide APIs, Part I: Analytical Consideration Read source

    Used Here For

    Illustrating the real analytical steps behind a legitimate peptide purity claim.

    Good For

    Understanding the analytical control practices serious peptide manufacturers use.

    Not For

    Assuming all sellers follow these control strategies.

    BioPharm International, 2014 (PolyPeptide Group copy)